Perkins Coie Trust Co held its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 593 shares of the medical research company’s stock at the end of the second quarter. Perkins Coie Trust Co’s holdings in Thermo Fisher Scientific were worth $103,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Proficio Capital Partners LLC raised its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Independent Portfolio Consultants Inc. raised its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer raised its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the period. FNY Managed Accounts LLC bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $153,000. Finally, Penserra Capital Management LLC raised its stake in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares during the period. 83.52% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Inc (TMO) traded up 0.78% during midday trading on Wednesday, reaching $181.93. The company’s stock had a trading volume of 550,103 shares. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The company has a 50 day moving average price of $176.80 and a 200 day moving average price of $167.41. The firm has a market cap of $70.97 billion, a price-to-earnings ratio of 31.70 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same quarter last year, the business posted $2.03 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc will post $9.33 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is presently 10.45%.

COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Inc (TMO) Stake Maintained by Perkins Coie Trust Co” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-stake-maintained-by-perkins-coie-trust-co/1532277.html.

Several analysts recently commented on the company. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 target price on the stock in a report on Tuesday, August 1st. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Finally, Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. One investment analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $188.56.

In related news, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,958 shares of company stock valued at $6,765,077. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.